Keyphrases
Systemic Lupus Erythematosus
86%
Lupus
63%
Rheumatology
45%
Systemic Lupus Erythematosus Patient
38%
Multi-ethnic
34%
Latin American
31%
COVID-19
29%
Damage Accrual
28%
Remission
26%
Peruvian
25%
Rheumatic Diseases
20%
Latin America (LATAM)
20%
Disease Activity
19%
SLE Disease Activity Index (SLEDAI)
19%
Health-related Quality of Life
17%
Rheumatoid Arthritis
14%
Low Disease Activity
13%
Damage Index
13%
Autoimmune Disease
13%
Confidence Interval
12%
Multivariable
12%
American College of Rheumatology
12%
Systemic Lupus International Collaborating Clinics
12%
Age at Diagnosis
12%
Low Disease Activity State
11%
COVID-19 Pandemic
10%
Rheumatologists
10%
Risk Factors
10%
Pan American
10%
Patient Data
10%
American League
9%
Systematic Literature Review
9%
COVID-19 Outcomes
9%
Comorbidity
9%
Prednisone
9%
Disease Duration
9%
COVID-19 Vaccination
8%
SLICC
8%
Lumen
8%
Disease Activity Score
8%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
7%
American College of Rheumatology Criteria
7%
Epidemiology
7%
Immunosuppressive Drugs
7%
Severe Disease
7%
Mestizo
6%
Predictors of Remission
6%
Peru
6%
Hospitalization
6%
Latin American Countries
6%
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
59%
Rheumatology
52%
Disease Activity
41%
COVID-19
35%
Rheumatic Disease
26%
Disease
21%
Quality of Life
15%
SLEDAI
14%
Rheumatoid Arthritis
13%
Antimalarial Agent
9%
ANCA Associated Vasculitis
8%
Glucocorticoid
8%
Prednisone
7%
Immunosuppressive Drug
7%
Systematic Review
6%
COVID-19 Vaccination
6%
Patient-Data
6%
Cross Sectional Study
6%
Autoimmune Disease
6%
Symptom
6%
Disease Duration
6%
Clinical Feature
5%
Vasculitis
5%
Lupus Nephritis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
82%
Disease Activity
41%
Disease
31%
Remission
26%
Rheumatic Disease
21%
Rheumatoid Arthritis
15%
Vaccination Policy
14%
Autoimmune Disease
13%
Infection
11%
Immunosuppressive Agent
10%
Glucocorticoid
8%
Disease Duration
8%
Antimalarial Agent
7%
Comorbidity
7%
ANCA Associated Vasculitis
6%
Prednisone
6%
Lupus Erythematosus Nephritis
6%
Coronavirinae
5%
Wegener Granulomatosis
5%
